Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1Phase 2 1

Status

Completed 4Active not recruiting 2Unknown 1Terminated 1

Sponsor Class

OTHER 6INDUSTRY 4

Study Type

Interventional 4

Sponsor

Conditions

Tuberous Sclerosis 3Seizures 3Cancer Pain 1Behavior 1

Interventions

Paclitaxel 489Carboplatin 435Gemcitabine 394Docetaxel 385Cisplatin 359pembrolizumab 343Bevacizumab 335Nivolumab 261Pemetrexed 242Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 91

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Cannabidiol × Clear all
NCT05864846 2026-04-27

EpiCom

Jazz Pharmaceuticals

Phase 4 Completed
79 enrolled

Behavior, Seizures, Tuberous Sclerosis

NCT06533657 2026-04-21

UTOPIA-1

ZYUS Life Sciences Inc.

Phase 2 Completed
11 enrolled

Cancer Pain

NCT02544763 2022-09-28

A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

Jazz Pharmaceuticals

Phase 3 Completed
224 enrolled 18 charts

Seizures, Tuberous Sclerosis

NCT02544750 2022-07-14

An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

Jazz Pharmaceuticals

Phase 3 Completed
199 enrolled 14 charts

Seizures, Tuberous Sclerosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡